Pharmacogenetics of Apolipoprotein E Gene During Lipid-Lowering Therapy: Lipid Levels and Prevention of Coronary Heart Disease

Pharmacogenomics - United Kingdom
doi 10.2217/14622416.9.10.1475
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Systematic Review of Lipid Lowering for Primary Prevention of Coronary Heart Disease in Diabetes

BMJ
2005English

The Role of Aggressive Lipid Lowering Therapy for Coronary Artery Disease

Juntendo Medical Journal
2019English

Apolipoprotein(a) Phenotypes, Lp(a) Concentration and Plasma Lipid Levels in Relation to Coronary Heart Disease in a Chinese Population: Evidence for the Role of the Apo(a) Gene in Coronary Heart Disease.

Journal of Clinical Investigation
Medicine
1992English

Lipid Lowering and Plaque Regression. New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
1993English

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2017English

Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2005English

Low-Density Lipoprotein, Non–High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2003English

Controversial Issues of Pathogenesis and Lipid-Lowering Therapy of Atherosclerosis

Clinical pharmacology and therapy
2019English

The Effects of Lipid-Lowering Therapy on Graft Patency in Coronary Bypass Surgery Patients

Heart Surgery Forum
SurgeryCardiovascular MedicineCardiology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy